U.S. Gas Utilities Stock News

NasdaqGM:IRON
NasdaqGM:IRONBiotechs

A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings

Disc Medicine stock reacts after recent share price moves Disc Medicine (IRON) has drawn attention after recent share price swings, including a 5.0% gain over the past day, offset by declines over the past week, month, and past 3 months. See our latest analysis for Disc Medicine. The latest 1 day share price gain sits against weaker short term momentum, with the 30 day share price return of 19.43% decline and 90 day share price return of 29.97% decline contrasting with a 1 year total...
NasdaqGS:ERII
NasdaqGS:ERIIMachinery

A Look At Energy Recovery (ERII) Valuation After PX Q650 Desalination Launch

Why the PX Q650 launch matters for Energy Recovery (ERII) investors Energy Recovery (ERII) has drawn fresh attention after launching its PX Q650 Pressure Exchanger for desalination, combining higher flow capacity, very high stated efficiency, and extended warranties aimed at long-life plant operations. See our latest analysis for Energy Recovery. The PX Q650 launch comes on the heels of Energy Recovery’s recent earnings update. It arrives at a time when the stock has seen a 4.81% 1 day share...
NYSE:DT
NYSE:DTSoftware

Dynatrace (DT) Is Up 5.9% After EVP Share Purchase And AI Platform Spotlight – Has The Bull Case Changed?

In late February and early March 2026, Dynatrace drew attention as Executive Vice President Stephen McMahon bought 3,000 company shares for about US$107,250 and the firm highlighted its artificial intelligence-driven observability platform at Morgan Stanley’s Technology, Media & Telecom Conference in San Francisco. This combination of insider buying and a public focus on AI-enabled growth and raised profit guidance adds weight to Dynatrace’s existing growth and innovation story for...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Is New HIV Switch Data Reframing the Investment Case for Gilead Sciences’ Lenacapavir Platform (GILD)?

In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen maintained virologic suppression and was generally well tolerated, proving noninferior to both complex multi-tablet regimens and guideline-recommended single-tablet therapy through Week 48. This potential new once-daily option could simplify treatment for people living with HIV who are currently on complex regimens, reinforcing...
NasdaqGS:HTZ
NasdaqGS:HTZTransportation

How Investors May Respond To Hertz Global Holdings (HTZ) Narrowing Losses And Pershing Square’s Comeback Framing

Hertz Global Holdings, Inc. reported past fourth-quarter 2025 sales of US$2,028 million versus US$2,040 million a year earlier, with its quarterly net loss narrowing to US$194 million from US$479 million; full-year 2025 sales were US$8.50 billion versus US$9.05 billion, while the annual net loss improved to US$747 million from US$2.86 billion. Pershing Square’s 2025 commentary framed Hertz as an emerging comeback story, highlighting a refreshed fleet, higher utilization, and the company’s...
NYSE:BHVN
NYSE:BHVNBiotechs

Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration

In March 2026, Biohaven Ltd. reported fourth-quarter and full-year 2025 results showing its net loss narrowed to US$145.56 million for the quarter and US$738.82 million for the year, alongside reduced basic loss per share. On the same day, Biohaven also filed a US$134.78 million shelf registration for nearly 11.7 million common shares tied to an employee stock ownership plan, highlighting ongoing efforts to access capital and incentivize staff. We will now examine how Biohaven’s narrower...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Will T. Rowe Price’s New UK Retirement Lead (TROW) Subtly Reframe Its Long‑Term Strategy?

T. Rowe Price has appointed Richard Parkin as head of UK retirement, effective 9 March 2026, bringing over 35 years of pensions and retirement experience from roles at BNY Investments, Fidelity International, and key industry bodies. Parkin’s remit to shape the firm’s UK retirement strategy across retail and institutional channels highlights T. Rowe Price’s focus on expanding retirement solutions alongside its growing assets under management and earnings base. Next, we’ll examine how...
NasdaqGM:IESC
NasdaqGM:IESCConstruction

Does IES Holdings (IESC) Director Share Sale Recast the Story on Governance and Capital Allocation?

IES Holdings recently held its 2026 Annual Stockholders Meeting, where all director nominees were elected and Ernst & Young was ratified as auditor, while Director Todd Cleveland sold 2,500 shares, trimming his personal stake. Together with ongoing attention on the Gulf Island acquisition, these governance developments are sharpening investor focus on how IES allocates capital and manages oversight. Next, we’ll examine how the director’s share sale and refreshed governance framework shape...
NasdaqGS:CHDN
NasdaqGS:CHDNHospitality

Does Churchill Downs (CHDN) Revenue-Earnings Split Recast Its Gaming-Led Growth Strategy?

Churchill Downs Incorporated has released its fourth-quarter and full-year 2025 results, showing higher revenue of US$665.9 million for the quarter and US$2.93 billion for the year, but lower net income of US$51.3 million and US$383 million respectively compared with the prior year. The company also opened Marshall Yards Racing & Gaming in Calvert City, Kentucky in February 2026, adding its eighth historical horse racing venue in the state and further tying gaming operations to purse funding...
NasdaqGS:ZVRA
NasdaqGS:ZVRAPharmaceuticals

Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA)

Zevra Therapeutics, Inc. has reported its 2025 results, with full-year sales rising to US$106.47 million and net income reaching US$83.23 million, alongside fourth-quarter revenue of US$34.1 million and adjusted earnings of US$1.16 per share. Alongside these results, Zevra filed a US$22.86 million employee stock offering and named veteran finance executive Justin Renz as its new Chief Financial Officer, underscoring a focus on commercial scale-up and corporate development. We’ll now examine...
NasdaqGS:MQ
NasdaqGS:MQDiversified Financial

Marqeta (MQ) Valuation Check After Q4 Results And 2026 Growth Outlook

Marqeta (MQ) is back in focus after its fourth quarter 2025 update, which paired higher reported sales and a sharply smaller net loss with fresh 2026 guidance on revenue and gross profit growth. See our latest analysis for Marqeta. Marqeta’s earnings update and 2026 guidance have arrived after a softer patch in the stock. The 7 day share price return of 4.88% contrasts with a 90 day share price return of negative 15.35% and a 3 year total shareholder return of negative 3.09%. This suggests...
NYSE:OXY
NYSE:OXYOil and Gas

Occidental Petroleum (OXY) Valuation Check As Expanded Debt Buyback And Bondholder Support Draw Focus

Occidental Petroleum (OXY) is back in focus after it expanded the size of its cash tender offers to repurchase up to US$1.2b of outstanding notes and secured key bondholder consents. See our latest analysis for Occidental Petroleum. Occidental’s expanded tender offer and strong early bondholder participation come as the share price trades at US$55.02, with a 30 day share price return of 18.81% and year to date share price return of 29.83%. The 5 year total shareholder return of 100.16%...
NYSE:HTGC
NYSE:HTGCCapital Markets

Assessing Hercules Capital (HTGC) Valuation After Recent Share Price Weakness

Recent share performance and what it means for investors Hercules Capital (HTGC) has drawn investor attention after a recent pullback, with the stock showing negative returns over the past month and past 3 months, alongside a weaker move over the past year. At a last close of US$14.67, Hercules Capital sits below its recent levels. Returns of 76.11% over 3 years and 53.64% over 5 years provide a longer term contrast to its shorter term performance. See our latest analysis for Hercules...
NYSE:RMD
NYSE:RMDMedical Equipment

Assessing ResMed (RMD) Valuation As New Greenwood Distribution Hub Targets North American Growth

What ResMed’s new Greenwood hub could mean for the stock ResMed (RMD) is opening a new distribution center in Greenwood, Indiana, planned to start operations in 2027. The facility is intended to improve delivery coverage and speed for its sleep and respiratory care products across North America. See our latest analysis for ResMed. At a share price of US$252.93, ResMed has had a softer patch recently with a 30 day share price return of a 6.88% decline, even though its 1 year total shareholder...
NasdaqGM:KYMR
NasdaqGM:KYMRBiotechs

A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change

Why Kymera’s latest update matters for shareholders Kymera Therapeutics (KYMR) has put several big items on the table at once, including a planned US$500 million at the market equity offering, wider quarterly and full year losses, and a new Chief Development Officer. These moves come as the company continues to invest in its protein degradation pipeline, and they raise practical questions for you around dilution, funding flexibility, and how leadership changes might influence the pace and...
NYSE:CPRI
NYSE:CPRILuxury

A Look At Capri Holdings (CPRI) Valuation After Tyler Reddien’s Appointment As CFO And COO

Leadership shift and upcoming conference draw attention to Capri Holdings stock The recent decision by Capri Holdings (CPRI) to appoint Tyler Reddien as both Chief Financial Officer and Chief Operating Officer, along with an upcoming appearance at Citi’s 2026 Global Consumer & Retail Conference, has brought fresh attention to the stock. See our latest analysis for Capri Holdings. Capri Holdings' share price has softened over the past year, with a 30 day share price return of a 9.22% decline...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

The Bull Case For Belite Bio (BLTE) Could Change Following Steeply Wider 2025 Net Losses – Learn Why

Belite Bio, Inc reported fourth-quarter and full-year 2025 results, with net loss widening to US$25.32 million for the quarter and US$77.61 million for the year, compared with US$10.1 million and US$36.14 million respectively in the prior periods. The company is now absorbing materially higher per-share losses as it scales R&D and commercial infrastructure ahead of potential Tinlarebant approvals in rare retinal diseases. We’ll now examine how Belite Bio’s significantly wider 2025 net loss...
NasdaqGS:WTW
NasdaqGS:WTWInsurance

How Investors May Respond To Willis Towers Watson (WTW) Dividend Hike And New Digital Infrastructure Push

In late February 2026, Willis Towers Watson reported fourth-quarter 2025 results that beat expectations, expanded operating margins, and approved a regular quarterly cash dividend of US$0.96 per share, a 4% increase from the prior quarter. Alongside these results, WTW created new leadership roles and launched a Global Digital Infrastructure Group, highlighting its push into specialized, cross-functional risk solutions for data center and digital infrastructure clients. Now we’ll examine how...
NYSE:NFG
NYSE:NFGGas Utilities

Assessing National Fuel Gas (NFG) Valuation After Recent Share Price Strength

Why National Fuel Gas is on investors’ radar National Fuel Gas (NFG) has drawn fresh attention after recent share price moves, with the stock showing double digit total returns over the past 3 months and year. This performance has prompted closer scrutiny of its fundamentals. See our latest analysis for National Fuel Gas. Recent trading has been relatively steady, with a 30 day share price return of 8.3% and a 90 day share price return of 13.4%. The 1 year total shareholder return of 28.2%...
NasdaqGS:TIGO
NasdaqGS:TIGOWireless Telecom

Why Millicom (TIGO) Is Down 6.6% After Reporting a Surge in 2025 Net Income

In February 2026, Millicom International Cellular S.A. reported fourth-quarter 2025 sales of US$1,652 million and net income of US$252 million, with basic earnings per share from continuing operations rising to US$1.51. For full-year 2025, Millicom’s net income increased to US$1.32 billions on essentially unchanged sales of US$5.82 billions, highlighting a sharp improvement in profitability relative to revenue growth. We will now examine how this surge in full-year profitability might...
NYSE:TT
NYSE:TTBuilding

Trane Technologies (TT) Is Down 8.3% After Insider Sale And Premium Valuation Jitters Has The Bull Case Changed?

In recent days, Trane Technologies faced pressure after going ex-dividend amid concerns that its shares are trading at a premium to industry peers, while an executive’s share sale added to questions about near-term confidence. At the same time, the company advanced its sustainability agenda with new climate-smart cooling programs in India and Africa and launched an energy-efficient chiller tailored for Asia Pacific data centers, underscoring its push into high-demand, lower-emission cooling...
NasdaqGS:TRIP
NasdaqGS:TRIPInteractive Media and Services

Assessing Tripadvisor (TRIP) Valuation After Easing AI Fears And Review System Update

Why Tripadvisor Is Back in Focus Investor worries about artificial intelligence cutting out online travel intermediaries have eased after reports that OpenAI will lean on existing booking platforms instead of handling reservations directly inside ChatGPT. For Tripadvisor (TRIP), that shift, combined with its 2026 update to a more heavily weighted review system that factors in recency, volume, and fraud detection, has pushed attention back to the quality of its travel guidance and how it...
NYSE:DEC
NYSE:DECOil and Gas

A Look At Diversified Energy (NYSE:DEC) Valuation After Its Follow-On Equity Offering And New Shelf Registration

Diversified Energy (DEC) has moved to raise fresh capital by completing a roughly US$108.4m follow-on equity offering and filing an omnibus shelf registration that covers common stock, preferred stock, warrants and units. See our latest analysis for Diversified Energy. The follow on offering comes after a run of company updates, including 2025 earnings, new production guidance for 2026, a fresh share buyback authorization and an acquisition agreement in East Texas. It arrives as the share...
NYSE:QBTS
NYSE:QBTSSoftware

Assessing D-Wave Quantum’s (QBTS) Valuation After Mixed Earnings And Growing Commercial Traction

D-Wave Quantum (QBTS) is back in focus after its fourth quarter and full year 2025 earnings, where revenue and losses moved in different directions and raised fresh questions about risk and opportunity. See our latest analysis for D-Wave Quantum. Since those earnings, investors have been wrestling with mixed signals, and the stock reflects that: despite a 1-day share price return of 2.42%, the 90-day share price return of negative 32.79% contrasts sharply with a very large 1-year total...